Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...
Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, and Vicore Pharma, a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 ...
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...
Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel ...
Preclinical Data Highlight TP-317’s Anti-Inflammatory, Epithelial Barrier-Protective Effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback